Mineralys Therapeutics, Common Stock Book Value Per Share
| MLYS Stock | 14.40 0.52 3.75% |
Mineralys Therapeutics, Common fundamentals help investors to digest information that contributes to Mineralys Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Mineralys Stock. The fundamental analysis module provides a way to measure Mineralys Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mineralys Therapeutics, stock.
| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 6.66 | 7.00 | |
| Tangible Book Value Per Share | 6.66 | 7.00 |
Mineralys | Book Value Per Share |
Mineralys Therapeutics, Common Company Book Value Per Share Analysis
Mineralys Therapeutics,'s Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Mineralys Therapeutics, Book Value Per Share | 5.84 X |
Most of Mineralys Therapeutics,'s fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mineralys Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Mineralys Book Value Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Mineralys Therapeutics, is extremely important. It helps to project a fair market value of Mineralys Stock properly, considering its historical fundamentals such as Book Value Per Share. Since Mineralys Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mineralys Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mineralys Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
| Competition |
Mineralys Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, the book value per share of Mineralys Therapeutics, Common is about 5.836 times. This is 443.29% lower than that of the Biotechnology sector and 102.35% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.7% higher than that of the company.
Mineralys Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in book value per share category among its peers.
Mineralys Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mineralys Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mineralys Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Mineralys Fundamentals
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.28 | ||||
| Current Valuation | 693.3 M | ||||
| Shares Outstanding | 49.73 M | ||||
| Shares Owned By Insiders | 2.55 % | ||||
| Shares Owned By Institutions | 97.45 % | ||||
| Number Of Shares Shorted | 1.59 M | ||||
| Price To Book | 2.47 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) | ||||
| Total Debt | 10.48 M | ||||
| Book Value Per Share | 5.84 X | ||||
| Cash Flow From Operations | (81.17 M) | ||||
| Short Ratio | 14.21 X | ||||
| Earnings Per Share | (2.76) X | ||||
| Target Price | 33.0 | ||||
| Number Of Employees | 28 | ||||
| Market Capitalization | 716.06 M | ||||
| Total Asset | 251.64 M | ||||
| Retained Earnings | (124.71 M) | ||||
| Working Capital | 238.62 M | ||||
| Net Asset | 251.64 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.